Improved prognosis for biomarkers in breast cancer

被引：12

作者：

Dowsett, M ^{[1
]}

机构：

[1] Royal Marsden NHS Trust, Acad Dept Biochem, London SW3 6JJ, England

来源：

LANCET | 1998年 / 351卷 / 9118期

关键词：

D O I：

10.1016/S0140-6736(05)78743-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1753 / 1754

页数：2

相关论文

共 16 条

[1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
Aas, T
Borresen, AL
Geisler, S
SmithSorensen, B
Johnsen, H
Varhaug, JE
Akslen, LA
Lonning, PE
[J]. NATURE MEDICINE, 1996, 2 (07) : 811 - 814
[2] ABE O, 1992, LANCET, V339, P71
[3] neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
Andrulis, IL
Bull, SB
Blackstein, ME
Sutherland, D
Mak, C
Sidlofsky, S
Pritzker, KPH
Hartwick, RW
Hanna, W
Lickley, L
Wilkinson, R
Qizilbash, A
Ambus, U
Lipa, M
Weizel, H
Katz, A
Baida, M
Mariz, S
Stoik, G
Dacamara, P
Strongitharm, D
Geddie, W
McCready, D
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1340 - 1349
[4] BARTLETT K, 1993, LANCET, V341, P1293
[5] Bast RC, 1998, J CLIN ONCOL, V16, P793
[6] DRESSLER LG, 1992, J NATL CANCER I MONO, V11, P167
[7] *EARL BREAST CANC, 1992, LANCET, V339, P1
[8] ELLEDGE RM, 1993, ANNU REV MED, V44, P201, DOI 10.1146/annurev.med.44.1.201
[9] bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
Elledge, RM
Green, S
Howes, L
Clark, GM
Berardo, M
Allred, DC
Pugh, R
Ciocca, D
Ravdin, P
OSullivan, J
Rivkin, S
Martino, S
Osborne, CK
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1916 - 1922
[10] Preoperative chemotherapy induces apoptosis in early breast cancer
Ellis, PA
Smith, IE
McCarthy, K
Detre, S
Salter, J
Dowsett, M
[J]. LANCET, 1997, 349 (9055) : 849 - 849